rAAV PCCA/PCCB Gene Transfer for Propionic Acidemia Enzyme Deficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for propionic acidemia, such as dietary restrictions and antibiotics, do not address the underlying enzyme deficiency causing the disease, leading to poor long-term prognosis for patients.
Innovation Solution
Development of recombinant adeno-associated viral vectors (rAAV) that deliver functional PCCA or PCCB genes to patients with propionic acidemia, using AAV capsids and vector genomes containing specific sequences for gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary restriction and antibiotic therapy are used to manage propionic acidemia, then symptoms can be controlled temporarily, but the underlying enzyme deficiency remains untreated leading to poor long-term prognosis
Solution Approach 1:
The patent applies preliminary action by administering gene therapy before the disease progresses to severe stages. The rAAV vectors deliver functional PCCA or PCCB genes to hepatocytes in advance, enabling the liver to produce functional propionyl-CoA carboxylase enzyme before critical metabolic crises occur, thus improving long-term prognosis while avoiding complex lifelong dietary management
Solution Approach 2:
The patent uses recombinant adeno-associated virus (rAAV) vectors as intermediaries to deliver therapeutic genes. The AAV capsids serve as mediators that transport the functional PCCA or PCCB coding sequences into liver cells, enabling enzyme production without requiring complex dietary restrictions or antibiotics. This intermediary approach simplifies treatment while providing durable therapeutic effect
2Reliability
If liver transplantation is performed to address propionic acidemia, then enzyme deficiency can be corrected, but the procedure is invasive and carries significant surgical risks
Solution Approach 1:
The patent extracts only the essential therapeutic element (functional PCCA or PCCB gene) from the complex liver transplantation procedure. Instead of replacing the entire liver organ, the invention delivers just the missing genetic information to native hepatocytes using rAAV vectors, correcting the enzyme deficiency without exposing patients to surgical risks associated with liver transplantation
Solution Approach 2:
The patent creates a functional copy of the defective PCCA or PCCB gene and introduces it into patient's liver cells using rAAV vectors. This genetic copying approach restores enzyme function by providing a working version of the mutated gene, achieving the therapeutic goal of liver transplantation without the need for actual organ replacement and its associated surgical hazards
3Ease of operation
If complex combinations of nutritional, cofactor, and antibiotic therapy are administered, then disease symptoms can be managed, but the treatment regimen becomes increasingly complex and difficult to maintain
Solution Approach 1:
The patent merges multiple separate therapeutic interventions (dietary management, cofactor supplementation, antibiotic therapy) into a single unified treatment approach. By delivering the functional gene therapeutically using rAAV vectors, the invention consolidates what would otherwise require complex multi-modal management into one administration that addresses the root cause of the disease, thereby improving both ease of operation and reliability of disease control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The rAAV vectors effectively transfer functional PCCA or PCCB genes, potentially addressing the enzyme deficiency and improving the long-term prognosis for patients with propionic acidemia.
Implementation Method 1
recombinant adeno-associated viral vectors (rAAV) that deliver functional PCCA or PCCB genes to patients with propionic acidemia
Data Source
AI summary
This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical (compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase α-subunit (PCCA) or mutations in propionyl-CoA carboxylase β-subunit (PCCB).